Shares of SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH – Get Free Report) crossed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $65.67 and traded as high as $67.45. SPDR S&P Pharmaceuticals ETF shares last traded at $67.37, with a volume of 639,639 shares trading hands.
SPDR S&P Pharmaceuticals ETF Trading Up 4.0%
The firm has a 50 day moving average price of $65.67 and a 200 day moving average price of $61.97. The stock has a market capitalization of $501.91 million, a PE ratio of 14.28 and a beta of 0.62.
Institutional Trading of SPDR S&P Pharmaceuticals ETF
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Western Wealth Management LLC bought a new position in shares of SPDR S&P Pharmaceuticals ETF in the first quarter worth about $34,000. Fifth Third Bancorp bought a new position in shares of SPDR S&P Pharmaceuticals ETF during the 1st quarter valued at approximately $39,000. Team Financial Group LLC bought a new position in shares of SPDR S&P Pharmaceuticals ETF during the 3rd quarter valued at approximately $65,000. TD Waterhouse Canada Inc. bought a new position in shares of SPDR S&P Pharmaceuticals ETF during the 2nd quarter valued at approximately $200,000. Finally, Simplex Trading LLC purchased a new stake in SPDR S&P Pharmaceuticals ETF in the 3rd quarter worth approximately $190,000.
About SPDR S&P Pharmaceuticals ETF
SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Further Reading
- Five stocks we like better than SPDR S&P Pharmaceuticals ETF
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for SPDR S&P Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
